Our company’s R&D activities are focusing on discovery and clinical applications of molecular targeted radiotherapy. Related publications can be found in the Targeted Radiotherapy section. Moreover, 3BP is doing research within its drug discovery collaborations and around technology development.  Below you can find a selection of our Discovery Technologies publications.

  1. Lucey M, Pickford P, Bitsi S, Minnion J, Ungewiss J, Schoeneberg K, Rutter GA, Bloom SR, Tomas A, Jones B. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol Metab. 2020 Apr 8:100991. doi: 10.1016/j.molmet. 2020.100991. [Epub ahead of print]
  2. Ungewiss J, Gericke S, Boriss H. Determination of the Plasma Protein Binding of Liraglutide Using the EScalate Equilibrium Shift Assay. J Pharm Sci. 2019 Mar;108(3):1309-1314. doi: 10.1016/j.xphs.2018.10.018. Epub 2018 Oct 17. PubMed PMID: 30342006.
  3. Dockal M, Hartmann R, Fries M, Thomassen MC, Heinzmann A, Ehrlich H, Rosing J, Osterkamp F, Polakowski T, Reineke U, Griessner A, Brandstetter H, Scheiflinger F. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem. 2014 Jan 17;289(3):1732-41. doi: 10.1074/jbc.M113.533836. Epub 2013 Nov 25. PubMed PMID: 24275667
  4. Dockal M, Hartmann R, Fries M, Prohaska K, Pachlinger R, Polakowski T, Brandstetter J, Rosing J, Scheiflinger F Crystal Structure Of Tissue Factor Pathway Inhibitor (TFPI) Kunitz Domain 1 and 2 In Complex With An Inhibitory Cyclic Peptide. Blood 2013; 122 (21): 453. doi: 10.1182/blood.V122.21.453.453.